Home » Healthcare » Bovine Tuberculosis Diagnosis Market
Bovine Tuberculosis Diagnosis Market By Test Type (Serological Tests, Molecular Diagnostic Tests, Traditional Tests); By Animal Type (Dairy Cattle, Beef Cattle, Buffalo and Bison); By Sample Type (Blood, Milk, Tissue / Lesion, Fecal and Environmental Swab); By End User (Veterinary Reference Laboratories, On-Farm / Point-of-Care Settings, Government Agencies and Animal Health Departments, Academic and Research Institutes); By Region – Growth, Share, Opportunities & Competitive Analysis, 2025 – 2032
The global Bovine Tuberculosis Diagnosis Market size was estimated at USD 814.6 million in 2025 and is expected to reach USD 1086.47 million by 2032, growing at a CAGR of 4.2% from 2025 to 2032. Demand is primarily supported by expanding routine surveillance and confirmatory testing needs across commercial herds, driven by eradication programs, animal movement controls, and export compliance requirements. Increasing deployment of field-oriented testing workflows and faster laboratory turnaround times further supports steady volume growth across both screening and supplemental testing pathways.
REPORT ATTRIBUTE
DETAILS
Historical Period
2020-2024
Base Year
2025
Forecast Period
2026-2032
Bovine Tuberculosis Diagnosis Market Size 2025
USD 814.6 million
Bovine Tuberculosis Diagnosis Market, CAGR
4.2%
Bovine Tuberculosis Diagnosis Market Size 2032
USD 1086.47 million
Key Market Trends & Insights
The market is projected to expand from USD 814.6 million (2025) to USD 1086.47 million (2032) at a 4.2% CAGR (2025–2032).
Traditional Tests accounted for the largest share of 43.5% in 2025, reflecting the continued use of established screening protocols in routine surveillance programs.
On-Farm / Point-of-Care Settings represented 52.6% share in 2025, indicating an operational shift toward faster decision-making at herd level.
Dairy Cattle held 65.2% share in 2025, supported by higher testing cadence and tighter quality and movement compliance in dairy supply chains.
North America contributed 35.8% of revenue in 2025, supported by structured surveillance, reference lab capacity, and consistent program funding.
Segment Analysis
Testing demand is shaped by a combination of routine surveillance, herd breakdown investigations, and pre-movement compliance workflows, which collectively sustain recurring volumes across both laboratory and farm-based settings. Buyers prioritize solutions that reduce false negatives, improve time-to-result, and fit within real-world veterinary workflows, especially where herd-level decisions are time-sensitive. As a result, markets are gradually expanding beyond single-test dependence toward layered testing strategies that balance field practicality with confirmatory rigor.
Technology adoption is also influenced by sample accessibility and logistics across geographies. Blood remains a commonly used sample for scalable processing and compatibility with multiple assay workflows, while milk and environmental sampling are increasingly used where they can reduce animal handling or align with routine collection practices. Across end users, government agencies and animal health departments maintain foundational demand through surveillance requirements, while reference laboratories and academic institutes support validation and method refinement that enable broader adoption.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
Traditional Tests accounted for the largest share of 43.5% in 2025. These approaches remain embedded in surveillance frameworks because they are well-standardized, widely understood by field teams, and supported by long-established procurement pathways. Their operational familiarity enables consistent deployment at scale, particularly in routine screening cycles. Supplemental use of serological and molecular options tends to expand around confirmatory needs and higher-risk herd situations rather than displacing traditional methods outright.
By Animal Type Insights
Dairy Cattle accounted for the largest share of 65.2% in 2025. Dairy herds typically face tighter monitoring and more frequent testing cycles due to supply chain requirements, movement controls, and quality assurance expectations. Larger herd sizes and higher-density operations can increase exposure risk and strengthen the economic case for proactive surveillance. In addition, routine veterinary engagement and standardized farm management practices support more consistent diagnostics utilization in commercial dairy settings.
By Sample Type Insights
Blood accounted for the largest share of 41.9% in 2025. Blood-based sampling is practical for scaled surveillance and fits cleanly into both screening-aligned and confirmatory workflows across many programs. It also supports efficient transport and processing when centralized laboratories are used for interpretation and reporting. Continued improvements in handling protocols and test workflow integration further reinforce blood as the default sample in many settings.
By End User Insights
On-Farm / Point-of-Care Settings accounted for the largest share of 52.6% in 2025. Farm-side testing is expanding because it supports faster operational decisions, including isolation management, movement planning, and risk-based herd actions. Reduced turnaround times can lower the costs of uncertainty and improve compliance with control requirements. Even when confirmatory testing remains lab-based, farm-centric screening increases overall testing frequency and strengthens adoption of workflow-friendly tools.
Bovine Tuberculosis Diagnosis Market Drivers
Expansion of surveillance and disease-control programs in commercial herds
Bovine tuberculosis control relies heavily on regular testing, movement restrictions, and targeted surveillance, which keeps diagnostics demand structurally recurring. Programs often require routine screening cycles, follow-up testing for reactors, and additional checks for high-risk areas. These requirements increase the number of tests per herd over time and create stable baseline volumes. As animal movement and trade compliance become stricter, producers and agencies increase testing cadence to reduce outbreak and export risks.
For instance, in England’s High Risk Area, the UK Animal and Plant Health Agency (APHA) moved many herds from annual to six‑monthly surveillance under the government’s bTB eradication strategy in 2021–2024, effectively doubling routine test frequency for those herds.
Operational need for faster decision-making and reduced turnaround time
Farmers, veterinarians, and animal health departments prioritize shorter time-to-result to manage herd risk and reduce operational disruption. Faster decisions support isolation planning, movement approvals, and culling or segregation choices when needed. This strengthens demand for workflow-oriented solutions that fit real-world conditions, including simpler sampling and clearer interpretation. As a result, more testing shifts closer to care even when confirmatory work remains with reference laboratories.
For instance, Becton Dickinson’s MGIT culture system reduced mycobacterial culture turnaround for bovine tuberculosis from traditional 2–8‑week solid media protocols to under 7 days in liquid culture in field evaluations.
Gradual adoption of newer diagnostics alongside established testing pathways
The market is increasingly shaped by layered strategies that combine widely used screening tests with supplemental assays that improve detection in specific scenarios. Molecular diagnostics and serology are often positioned for confirmatory use, special investigations, and higher-risk herd conditions. This complements rather than replaces routine testing, increasing the number of tests performed per suspected case. Over time, broader validation, better workflow integration, and improved logistics support incremental expansion of advanced testing adoption.
Rising emphasis on zoonotic risk management and food chain assurance
Bovine tuberculosis is monitored not only for livestock productivity but also for zoonotic risk and food chain integrity. Producers, regulators, and processors seek stronger assurance that herds remain compliant with animal health requirements. This encourages continued investment in testing capacity and structured reporting, particularly in organized dairy and beef supply chains. As surveillance expands, demand for standardized kits, consistent consumables, and reliable lab services increases across regions.
Bovine Tuberculosis Diagnosis Market Challenges
Diagnostics performance can be constrained by sensitivity limitations of routine tests and variability in infection stage, which can lead to missed cases and repeated testing cycles. This creates operational burden for producers and agencies and can reduce confidence when results conflict across methods. Logistics challenges such as sample transport, laboratory capacity constraints, and access to skilled personnel can also slow turnaround time, especially outside major production hubs.
For instance, Zoetis’ VitalRADS teleradiology service offers STAT reads in under one hour and routine interpretations in about three hours, demonstrating how virtual laboratory capacity can compress turnaround times in remote or resource-limited locations.
Regulatory acceptance pathways and program standardization can slow adoption of newer methods, even when they offer operational benefits. Testing protocols are often embedded in national frameworks, making change management complex across field teams, labs, and reporting systems. Cost sensitivity remains a limiting factor, particularly where surveillance budgets are constrained or where producers bear a larger share of testing expenses. These factors collectively temper the pace of technology transition across markets.
Bovine Tuberculosis Diagnosis Market Trends and Opportunities
Demand is increasingly shifting toward workflow designs that reduce herd disruption and improve clarity of actionability, which supports broader use of farm-side screening tools and more efficient sample handling. Buyers are also seeking streamlined reporting, integration with animal health databases, and standardized interpretation to strengthen traceability and program compliance. These needs create opportunities for companies that can package diagnostics with operational enablement rather than selling standalone tests.
For instance, DeLaval’s inline electrical conductivity sensors integrated into automated milking systems continuously monitor individual quarters and have reported clinical mastitis detection sensitivities ranging from 60% to 85%, enabling real-time alerts with no additional animal handling.
A second opportunity is the expansion of multi-sample and multi-context surveillance strategies, including broader use of milk and environmental sampling where it can reduce handling and improve herd-level monitoring. Growth in organized dairy operations and export-linked beef supply chains increases demand for repeatable testing and quality assurance. As capacity expands, suppliers that provide training, service support, and stable consumables supply can strengthen long-term customer retention.
Regional Insights
North America
North America accounted for 35.8% share in 2025. Demand is supported by structured surveillance systems, stronger reference laboratory coverage, and consistent compliance requirements across commercial operations. Higher spend per test and a strong installed base of veterinary diagnostics workflows support revenue leadership. Adoption of complementary testing approaches also supports steady testing volumes in both screening and follow-up contexts.
Europe
Europe represented 26.7% share in 2025. The region benefits from formalized disease-control frameworks and established laboratory networks that support repeatable testing cycles. Movement controls and trade-oriented compliance reinforce consistent surveillance needs across herd types. Ongoing efforts to improve detection performance continue to encourage supplementary testing approaches where required.
Asia Pacific
Asia Pacific held 24.9% share in 2025. Growth is supported by expanding commercial dairy and beef operations and increasing attention to animal health management in organized supply chains. Testing penetration varies widely by country, but scaling herd sizes and modernization of veterinary services support market expansion. Wider adoption of efficient sampling and improved lab throughput is expected to support sustained growth.
Latin America
Latin America captured 7.1% share in 2025. Demand is strengthened in export-oriented supply chains and in areas where surveillance programs are being reinforced. However, uneven infrastructure and budget variability can limit testing intensity across markets. Suppliers that enable cost-efficient workflows and reliable consumables availability are well-positioned for growth.
Middle East & Africa
Middle East & Africa accounted for 5.5% share in 2025. The market is shaped by improving veterinary diagnostics capacity and gradual expansion of structured surveillance in selected geographies. Penetration remains lower due to infrastructure constraints and variable program maturity. Increasing focus on herd productivity and disease management in organized operations supports incremental demand growth.
Competitive Landscape
Competition is shaped by the ability to deliver reliable assays, support standardized workflows, and sustain consistent supply of kits and consumables across surveillance cycles. Vendors differentiate through test portfolio breadth across serology, molecular tools, and supporting workflow components that enable repeatability and reporting. Partnerships with veterinary labs, government programs, and large producers help strengthen recurring demand and long-term account stability. Service enablement, technical training, and integration support are increasingly important for customer retention.
Bio-Rad Laboratories is positioned as a major participant through immunoassay capabilities, laboratory workflow familiarity, and broad analytical tool expertise that aligns with surveillance-driven testing demand. The company’s strengths typically relate to scalable lab adoption, standardized kit performance, and compatibility with high-throughput environments. Portfolio adjacency across infectious disease testing and laboratory automation can support smoother workflow adoption for reference laboratories. Ongoing product optimization and service support remain important for sustained competitiveness in routine testing programs.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
In December 2024, the World Health Organization announced the first prequalification of a tuberculosis diagnostic test, a milestone that, while focused on human TB, is expected to indirectly benefit bovine tuberculosis diagnosis companies by validating similar molecular platforms and encouraging investment in cross-species TB assay development.
In May 2024, a team of researchers published results on a new ELISA test using a circulating Mycobacterium bovis Pks5 biomarker, demonstrating suitable sensitivity and specificity for bovine TB detection in dairy cows and creating an opportunity for diagnostic companies to license or translate this assay into commercial kits for field use.
Report Scope
Report Attribute
Details
Market size value in 2025
USD 814.6 million
Revenue forecast in 2032
USD 1086.47 million
Growth rate (CAGR)
4.2% (2025–2032)
Base year
2025
Forecast period
2026-2032
Quantitative units
USD million
Segments covered
By Test Type Outlook: Serological Tests, Molecular Diagnostic Tests, Traditional Tests; By Animal Type Outlook: Dairy Cattle, Beef Cattle, Buffalo and Bison; By Sample Type Outlook: Blood, Milk, Tissue / Lesion, Fecal and Environmental Swab; By End User Outlook: Veterinary Reference Laboratories, On-Farm / Point-of-Care Settings, Government Agencies and Animal Health Departments, Academic and Research Institutes
Regional scope
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
1. Introduction
1.1. Report Description
1.2. Purpose of the Report
1.3. USP & Key Offerings
1.4. Key Benefits for Stakeholders
1.5. Target Audience
1.6. Report Scope
1.7. Regional Scope 2. Scope and Methodology
2.1. Objectives of the Study
2.2. Stakeholders
2.3. Data Sources
2.3.1. Primary Sources
2.3.2. Secondary Sources
2.4. Market Estimation
2.4.1. Bottom-Up Approach
2.4.2. Top-Down Approach
2.5. Forecasting Methodology 3. Executive Summary 4. Introduction
4.1. Overview
4.2. Key Industry Trends 5. Global Bovine Tuberculosis Diagnosis Market
5.1. Market Overview
5.2. Market Performance
5.3. Impact of COVID-19
5.4. Market Forecast 6. Market Breakup by Test Type
6.1. Serological Tests
6.1.1. Market Trends
6.1.2. Market Forecast
6.1.3. Revenue Share
6.1.4. Revenue Growth Opportunity
6.2. Molecular Diagnostic Tests
6.2.1. Market Trends
6.2.2. Market Forecast
6.2.3. Revenue Share
6.2.4. Revenue Growth Opportunity
6.3. Traditional Tests
6.3.1. Market Trends
6.3.2. Market Forecast
6.3.3. Revenue Share
6.3.4. Revenue Growth Opportunity 7. Market Breakup by Animal Type
7.1. Dairy Cattle
7.1.1. Market Trends
7.1.2. Market Forecast
7.1.3. Revenue Share
7.1.4. Revenue Growth Opportunity
7.2. Beef Cattle
7.2.1. Market Trends
7.2.2. Market Forecast
7.2.3. Revenue Share
7.2.4. Revenue Growth Opportunity
7.3. Buffalo and Bison
7.3.1. Market Trends
7.3.2. Market Forecast
7.3.3. Revenue Share
7.3.4. Revenue Growth Opportunity 8. Market Breakup by Sample Type
8.1. Blood
8.1.1. Market Trends
8.1.2. Market Forecast
8.1.3. Revenue Share
8.1.4. Revenue Growth Opportunity
8.2. Milk
8.2.1. Market Trends
8.2.2. Market Forecast
8.2.3. Revenue Share
8.2.4. Revenue Growth Opportunity
8.3. Tissue / Lesion
8.3.1. Market Trends
8.3.2. Market Forecast
8.3.3. Revenue Share
8.3.4. Revenue Growth Opportunity
8.4. Fecal and Environmental Swab
8.4.1. Market Trends
8.4.2. Market Forecast
8.4.3. Revenue Share
8.4.4. Revenue Growth Opportunity 9. Market Breakup by End User
9.1. Veterinary Reference Laboratories
9.1.1. Market Trends
9.1.2. Market Forecast
9.1.3. Revenue Share
9.1.4. Revenue Growth Opportunity
9.2. On-Farm / Point-of-Care Settings
9.2.1. Market Trends
9.2.2. Market Forecast
9.2.3. Revenue Share
9.2.4. Revenue Growth Opportunity
9.3. Government Agencies and Animal Health Departments
9.3.1. Market Trends
9.3.2. Market Forecast
9.3.3. Revenue Share
9.3.4. Revenue Growth Opportunity
9.4. Academic and Research Institutes
9.4.1. Market Trends
9.4.2. Market Forecast
9.4.3. Revenue Share
9.4.4. Revenue Growth Opportunity 10. Market Breakup by Region
10.1. North America
10.1.1. United States
10.1.1.1. Market Trends
10.1.1.2. Market Forecast
10.1.2. Canada
10.1.2.1. Market Trends
10.1.2.2. Market Forecast
10.1.3. Mexico
10.1.3.1. Market Trends
10.1.3.2. Market Forecast
10.2. Europe
10.2.1. Germany
10.2.2. France
10.2.3. United Kingdom
10.2.4. Italy
10.2.5. Spain
10.2.6. Rest of Europe
10.3. Asia-Pacific
10.3.1. China
10.3.2. Japan
10.3.3. India
10.3.4. South Korea
10.3.5. Australia
10.3.6. Rest of Asia-Pacific
10.4. Latin America
10.4.1. Brazil
10.4.2. Argentina
10.4.3. Rest of Latin America
10.5. Middle East and Africa
10.5.1. GCC Countries
10.5.2. South Africa
10.5.3. Rest of Middle East & Africa 11. SWOT Analysis
11.1. Overview
11.2. Strengths
11.3. Weaknesses
11.4. Opportunities
11.5. Threats 12. Value Chain Analysis 13. Porters Five Forces Analysis
13.1. Overview
13.2. Bargaining Power of Buyers
13.3. Bargaining Power of Suppliers
13.4. Degree of Competition
13.5. Threat of New Entrants
13.6. Threat of Substitutes 14. Price Analysis 15. Competitive Landscape
15.1. Market Structure
15.2. Key Players
15.3. Profiles of Key Players
15.3.1. Bio-Rad Laboratories
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. Financials
15.3.1.4. SWOT Analysis
15.3.2. IDEXX Laboratories
15.3.3. Innovative Diagnostics SAS (IDvet)
15.3.4. Thermo Fisher Scientific
15.3.5. Zoetis
15.3.6. PBD Biotech
15.3.7. Abbott Laboratories
15.3.8. Enfer Group
15.3.9. QIAGEN
15.3.10. BioNote
15.3.11. AsureQuality
15.3.12. bioMérieux
15.3.13. Merck KGaA
15.3.14. INDICAL BIOSCIENCE 16. Research Methodology
Request A Free Sample
We prioritize the confidentiality and security of your data. Our promise: your information remains private.
Ready to Transform Data into Decisions?
Request Your Sample Report and Start Your Journey of Informed Choices
Providing the strategic compass for industry titans.
Frequently Asked Questions:
What is the market size of the Bovine Tuberculosis Diagnosis Market in 2025 and the forecast for 2032?
The market was USD 814.6 million in 2025 and is expected to reach USD 1086.47 million by 2032. This reflects sustained surveillance and confirmatory testing demand across commercial herds.
What is the CAGR for the Bovine Tuberculosis Diagnosis Market during 2025–2032?
The market is projected to grow at a CAGR of 4.2% from 2025 to 2032. Growth is supported by recurring surveillance cycles and expanding field-oriented workflows.
Which segment is the largest in 2025?
Dairy Cattle is the largest segment with 65.2% share in 2025. Higher testing cadence and structured compliance in dairy supply chains sustain dominance.
What are the key growth factors for the market?
Routine surveillance programs, movement controls, and export compliance keep testing volumes recurring. Adoption of more efficient workflows and supplemental testing approaches further supports growth.
Who are the leading companies in the market?
Key companies include Bio-Rad Laboratories, IDEXX Laboratories, Innovative Diagnostics SAS (IDvet), Thermo Fisher Scientific, and Zoetis, among others. Competition centers on portfolio breadth, workflow support, and supply reliability.
Which region leads the market in 2025?
North America leads with 35.8% revenue share in 2025. Structured surveillance systems and strong diagnostics infrastructure support regional leadership.
About Author
Shweta Bisht
Healthcare & Biotech Analyst
Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.
The global Breast Cancer Core Needle Biopsy Market size was estimated at USD 923.45 million in 2025 and is expected to reach USD 1,256.69 million by 2032, growing at a CAGR of 4.5% from 2025 to 2032.
The global Blood Platelets Market size was estimated at USD 6154.6 million in 2025 and is expected to reach USD 8044.68 million by 2032, growing at a CAGR of 3.9% from 2025 to 2032.
The global Bladder Cancer Therapeutics & Diagnostics Market size was estimated at USD 5690.23 million in 2025 and is expected to reach USD 8399.05 million by 2032, growing at a CAGR of 5.72% from 2025 to 2032.
The global Biotechnology Reagents Market size was estimated at USD 93,978.03 million in 2025 and is expected to reach USD 184,305.19 million by 2032, growing at a CAGR of 10.1% from 2025 to 2032.
The global Biohazard Bags Market size was estimated at USD 507.64 million in 2025 and is expected to reach USD 763.3 million by 2032, growing at a CAGR of 6% from 2025 to 2032.
The global Biguanides Market size was estimated at USD 18.64 million in 2025 and is expected to reach USD 23.88 million by 2032, growing at a CAGR of 3.6% from 2025 to 2032.
The global Biobetters Market size was estimated at USD 71522.2 million in 2025 and is expected to reach USD 123933.49 million by 2032, growing at a CAGR of 8.17% from 2025 to 2032.
The global Behavioral & Mental Health Software Market size was estimated at USD 7,477.6 million in 2025 and is expected to reach USD 22,148.34 million by 2032, growing at a CAGR of 16.78% from 2025 to 2032.
The global Axial Spondyloarthritis Market size was estimated at USD 6,707.16 million in 2025 and is expected to reach USD 9,066.55 million by 2032, growing at a CAGR of 4.4% from 2025 to 2032.
The Alopecia Treatment / Hair Loss Market is projected to grow from USD 3657.5 million in 2025 to an estimated USD 5257.27 million by 2032, with a compound annual growth rate (CAGR) of 5.3% from 2025 to 2032.
The Alzheimer’s Diagnosis and Drugs Market is projected to grow from USD 8,136.6 million in 2025 to an estimated USD 11,487.23 million by 2032, with a compound annual growth rate (CAGR) of 5.1% from 2025 to 2032.
Licence Option
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$4999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$5999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
